News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Chris Williams: New analysis of CD3/CD8 TILs in QUASAR trial
Photo of Chris Williams taken from Chris Williams/X
Aug 3, 2024, 00:15

Chris Williams: New analysis of CD3/CD8 TILs in QUASAR trial

Chris Williams, Medical oncologist at Leeds Hospitals, shared on X:

“Adjuvant chemotherapy decisions are complex in stage 2 colon cancer.

New analysis of CD3/CD8 TILs in QUASAR trial.

1st in early CRC RCT (colorectal cancer randomized controlled trial)

Stronger prognostic effect than any routinely measured stage 2 ‘high risk’ feature

High vs low CD3 Score = 3x 5 years recurrence risk.”

Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial

Authors: Christopher J.M. Williams, Richard Gray, Robert K. Hills, Michael Shires, Liping Zhang, Zuo Zhao, Tracie Gardner, Nancy Sapanara, Xiao-Meng Xu, Isaac Bai, Dongyao Yan, Andrea Muranyi, Sarah Dance, Faranak Aghaei, Gemma Hemmings, Michael Hale, Uday Kurkure, Christoph Guetter, Susan D. Richman, Gordon Hutchins, Jenny F. Seligmann, Nicholas P. West, Shalini Singh, Kandavel Shanmugam and Philip Quirke.

Chris Williams: New analysis of CD3/CD8 TILs in QUASAR trial

Source: Chris Williams/X

adjuvant chemotherapy Andrea Muranyi cancer CD3/CD8 TILs Chris Williams Christoph Guetter Christopher J.M. Williams Colon cancer colorectal cancer CRC Dongyao Yan Faranak Aghaei Gemma Hemmings Gordon Hutchins Isaac Bai Jenny F. Seligmann Kandavel Shanmugam Leeds Hospitals Liping Zhang Michael Hale Michael Shires Nancy Sapanara Nicholas P. West OncoDaily Oncology Philip Quirke QUASAR trial randomized controlled trial RCT Richard Gray Robert K. Hills Sarah Dance Shalini Singh Susan D. Richman Tracie Gardner Uday Kurkure Xiao-Meng Xu Zuo Zhao
Special Coverage
Insight
Nov 4, 2024, 18:01
Highlights from JLCS24 by Hidehito Horinouchi
Dialogues
Nov 4, 2024, 17:52
Beyond the Cancer Diagnosis: Dialogue with Alique Topalian, Hosted by Adrian Pogacian
Blog
Nov 4, 2024, 17:34
Sachin Jain: The behaviors that we expect from every SCAN Rebel
Blog
Nov 4, 2024, 17:17
How Does Chemotherapy During Pregnancy Impact Breast Cancer Outcomes?
Drugs
Nov 4, 2024, 17:12
Talha Badar: Current FDA label for asciminib
Blog
Nov 4, 2024, 16:52
Eighteen Researchers and Mentors Selected for ASCO's Inaugural International Clinical Research Scholars Program in Latin America
Drugs
Nov 4, 2024, 16:51
Rahul Banerjee: What Changes Once SQ Isatuximab Approved?
Blog
Nov 4, 2024, 16:42
Journal of Geriatric Oncology - Decision-making preferences of carers of older adults with cancer
Blog
Nov 4, 2024, 16:31
Survival benefit of smoking cessation among cancer patients treated in the Tobacco Research and Treatment Program
Blog
Nov 4, 2024, 16:23
Jan Král: Insights on how genetic mutations vary by cancer type by Yakup Ergün
Blog
Nov 4, 2024, 16:16
Sachin Jain: We are often destined to disappoint our mentors
Blog
Nov 4, 2024, 16:04
Trijn Israels: Honoured to have won an award for Best Abstract at the SIOP meeting